Aardvark Therapeutics, Inc. Common Stock

NASDAQ:AARD

Biotechnology

Healthcare
$3.95 +2.36%

+$0.09 today

Market cap
$86.45M
Beta
4.47
P/E (TTM)
-1.2
EPS (TTM)
-$3.20
52W Low $3.35High $17.94

Volume 1.32M

Average 0.18M

AARD Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $16.57M rose 113.6% year over year, behind the +141.5% change in trailing-twelve-month research & development. Sequentially, it rose 15.9% from the prior quarter. Over 3 fiscal years it compounded at +89.7% a year.

Context

  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +113.6% toward the trailing-twelve-month pace of +141.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$16.57M+15.9% QoQ
Last fiscal yearDec 2025
$48.94M+181.8% YoY
LTMMar 2026
$57.75M+141.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+113.6%——
1 year+181.8%——
3-year CAGR+89.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
48.94M USD
Year-over-year change
+181.8%
3-year CAGR
+89.7%

Research & Development vs competitors

How AARD compares with its peers on the latest reported figures

  • AARD's LTM Mar 2026 research & development of $57.75M is the 7th highest of the 11 companies compared; the peer median is $63.62M.
  • Its year-over-year change of +141.5% is the highest of 11, against a peer median of +0.4%.
  • Over three fiscal years its annual growth of +89.7% compares with a peer median of +0.8%.
AARD Competitors Peer median
Research & Development for AARD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRBUCaribou Biosciences, Inc.LTM Mar 2026$94.52M -28.3%+10.0%843.7%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$91.32M -20.8%-13.4%131.9%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$82.1M -9.4%-6.8%290.9%
PYXSPyxis Oncology, Inc.LTM Mar 2026$76.25M +21.5%-5.1%550.2%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$64.86M +10.1%-2.5%91.2%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$62.37M -24.6%-10.1%27721.8%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$57.75M +141.5%+89.7%—
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$55.01M +74.4%+17.0%93235.6%
ZURAZura Bio LimitedLTM Mar 2026$46.35M +48.2%+21.1%—
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$40.3M -12.6%+4.1%—
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$27.18M +72.6%+29.4%—
Peer median (excluding AARD) $63.62M+0.4%+0.8%550.2%

Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development7.17M4.48M17.36M48.94M
Selling, General & Admin2.7M2.17M5.31M13.79M
Operating Expenses11.36M7.42M22.79M62.73M
Depreciation & Amortization110K97K16K36K
EBITDA(10.76M)(6.56M)(22.65M)(57.56M)
EBITDA Margin————
Operating Income(11.36M)(7.42M)(22.79M)(62.73M)
Operating Margin————
Interest Income120K1.42M2.41M5.14M
Interest Expense0000
Other Income / Expenses(2.2M)207K2.2M5.13M
Income Before Tax(13.56M)(7.21M)(20.59M)(57.59M)
Pre-Tax Margin————
Income Tax Expense0000
Net Income(13.56M)(7.21M)(20.59M)(57.59M)
Net Margin————
EPS (Basic)(0.63)(0.34)(0.95)(2.64)
EPS (Diluted)(0.63)(0.34)(0.95)(2.64)
Weighted Avg Shares21.38M21.38M21.7M21.82M
Weighted Avg Shares (Diluted)21.38M21.38M21.7M21.82M

Aardvark Therapeutics, Inc. Common Stock

NASDAQ:AARD

Intrinsic Alpha fair value

Locked

Current Price

$3.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.